Racial and ethnic differences in prescribing antihyperglycemic medications to persons with type 2 diabetes: An all of
Veronica J Brady1, Samuel Akyirem2, Nikhil Padhye1
1Cizik School of Nursing, The University of Texas Health Science Center at Houston, USA.
Aims:
This study aimed to determine prescribing patterns for newer antihyperglycemic agents among racial and ethnic minorities with type 2 diabetes (T2DM) using the All of Us study data.
Methods:
We conducted a cross-sectional analysis of electronic health records (EHR) data obtained from the All of Us research study data. We included data from 20,016 persons with T2DM. Participants were eligible for the study if they were 18 years or older, living with T2DM, and had complete data on all variables of interest.
Results:
Participants in the study were more likely to be > 55 years of age, identify as female, and non-Hispanic White. Nearly half of the participants were married or partnered and had a household income of less than $35,000 annually. Most participants had hypertension and obesity. Non-Hispanic Blacks had 14 % less odds of having a current or previous prescription of SGLT-2i and 28 % lower odds of receiving a prescription for a GLP-1RA.
Conclusions:
Despite known benefits to mitigating the risk for cardiorenal complications related to diabetes, there continue to be disparities in the prescribing of newer antihyperglycemic medications for racial and ethnic minorities.
Related Concept Videos
Stereotypes, Prejudice, and Discrimination
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...


